SCHEMBL2932666

SCHEMBL2932666

CCCCCCc1cc2c(cc1O)OC(=O)CC2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.43
KMT2A Q03164 8/20 0.43
HTT P42858 7/20 0.43
MAPT P10636 4/20 0.43
TYR P14679 2/20 0.43
TP53 P04637 1/20 0.43
CYP3A4 P08684 1/20 0.43
ALOX5 P09917 1/20 0.43
ALOX15 P16050 1/20 0.43
TSHR P16473 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
KDM4E B2RXH2 8/20 0.40
NOD2 Q9HC29 1/20 0.40
GAA P10253 6/20 0.39
HPGD P15428 5/20 0.39
ALDH1A1 P00352 4/20 0.39
POLB P06746 4/20 0.39
GLA P06280 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HIF1A Q16665 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2935573 1.00 MEN1 (0.43) MEN1KMT2AHTTMAPTTYR
SCHEMBL2934963 0.94 TYR (0.41) MEN1KMT2AHTTMAPTTYR
SCHEMBL2934063 0.84 ALDH2 (0.43) MAPTCYP3A4TSHRKDM4EGAA
SCHEMBL2305004 0.76 TYR (0.46) MEN1KMT2AHTTMAPTTYR
SCHEMBL2936330 0.75 CNR2 (0.38) ALDH2ALDH3A1
SCHEMBL11791192 0.74 ALDH2 (0.46) TSHRKDM4EHPGDALDH1A1GLA
SCHEMBL8867287 0.74 TYR (0.55) MEN1KMT2AHTTMAPTTYR
SCHEMBL27830618 0.74 DRD2 (0.39) MEN1KMT2AHTTMAPTTYR
SCHEMBL27830627 0.74 DRD2 (0.39) MEN1KMT2AHTTMAPTTYR
SCHEMBL28543753 0.73 BID (0.51) MEN1KMT2AHTTMAPTTYR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101917989-A Preparation containing chromane-2-one derivatives MERCK PATENT GMBH 2010-12-15 CN disclosed
US-20100291009-A1 PREPARATION COMPRISING CHROMAN-2-ONE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-11-18 US disclosed
US-20100291009-A1 PREPARATION COMPRISING CHROMAN-2-ONE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-11-18 US disclosed
US-20100291009-A1 PREPARATION COMPRISING CHROMAN-2-ONE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-11-18 US disclosed
EP-2229169-A1 PREPARATION CONTAINING CHROMANE-2-ONE DERIVATIVES Merck Patent GmbH (DE) 2010-09-22 EP disclosed
WO-2009089880-A1 PREPARATION CONTAINING CHROMANE-2-ONE DERIVATIVES MERCK PATENT GMBH (DE) 2009-07-23 WO disclosed
WO-2009089880-A1 PREPARATION CONTAINING CHROMANE-2-ONE DERIVATIVES MERCK PATENT GMBH (DE) 2009-07-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100291009-A1 PREPARATION COMPRISING CHROMAN-2-ONE DERIVATIVES RCC1, RB1, RCC2 MEN1 300/4885KMT2A 3069/4885HTT 1784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.